HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women

BACKGROUND: The sensitivity of estrogen receptor-positive breast cancers to tamoxifen treatment varies considerably, and the molecular mechanisms affecting the response rates are manifold. The human epidermal growth factor receptor-related receptor HER2 is known to trigger intracellular signaling ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Wege, Anja Kathrin, Chittka, Dominik, Buchholz, Stefan, Klinkhammer-Schalke, Monika, Diermeier-Daucher, Simone, Zeman, Florian, Ortmann, Olaf, Brockhoff, Gero
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247692/
https://www.ncbi.nlm.nih.gov/pubmed/30458882
http://dx.doi.org/10.1186/s13058-018-1072-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247692/
https://www.ncbi.nlm.nih.gov/pubmed/30458882
http://dx.doi.org/10.1186/s13058-018-1072-1

Ejemplares similares